Stock’s Buzz: AURORA CANNABIS IN COM NPV (ACBFF), Cannabis Science Inc (CBIS), Earth Science Tech Inc (ETST)

Stock’s Buzz: AURORA CANNABIS IN COM NPV (ACBFF), Cannabis Science Inc (CBIS), Earth Science Tech Inc (ETST)

Stock’s Buzz: AURORA CANNABIS IN COM NPV (ACBFF), Cannabis Science Inc (CBIS), Earth Science Tech Inc (ETST)

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) showing dropped/jumped of 2.34% and closed at $1.94, after gaining total volume of 960,679.00 shares. Its earnings per share (EPS) is -$0.05 and it has total market capitalization of $529.02 million and a total of 279.02 million outstanding shares.

Aurora Cannabis Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Cannabis Science Inc (OTCMKTS:CBIS) increased 8.27% closed at $0.0822 and traded with total volume of 19.79M shares, while the average trading remained 27.52M shares. During last trade its minimum price was $0.08 and it gained the highest price of $0.08. Its market capitalization was $181.51 million.

Cannabis Science Inc (CBIS) on March 8, 2017 announced the anticipated delivery of the first of our pre-designed greenhouses with full tracking and reporting protocols to be delivered this week for our California and Nevada operations.

“Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed product readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage,” stated CMO Dr. Allen Herman.

CBIS, Inc. has received several hundred emails inquiring about the timing of clinical research and the availability of treatment options. These inquiries cover the management of pain, peripheral neuropathies, cancer, and COPD. All inquiries are entered into our in-house database and we will be responding to each person as each targeted observational study officially commences. The studies will include some of the over 500 cannabinoids that have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis. Common plant cannabinoids (phytocannabinoids) include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). The pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis. Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions.

Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -14.36% and closed at $1.61, with the total traded volume of 89,367.00 shares. During last trade its minimum price was $1.55 and it gained its highest price of $1.88 and has a total of 40.91 million outstanding shares.

On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.

At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.

The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.

 

 

Leave a reply

0 Comments

There are no comments on this post.